The present analyses demonstrated that targeting cytokines, cytokine receptors, and inflammation-associated nuclear transcription factors, such as IL-1β, IL-1βR, TNF-α, and NF-κB, alone or in combination can significantly reduce the level of FPG, HbA1c, and CRP in patients with T2DM. The gene discussed is NFKB1; the disease is type 2 diabetes mellitus.